319 related articles for article (PubMed ID: 16235684)
1. Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application.
Ragel BT; Jensen RL; Gillespie DL; Prescott SM; Couldwell WT
J Neurosurg; 2005 Sep; 103(3):508-17. PubMed ID: 16235684
[TBL] [Abstract][Full Text] [Related]
2. Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.
Ragel BT; Jensen RL; Gillespie DL; Prescott SM; Couldwell WT
Cancer; 2007 Feb; 109(3):588-97. PubMed ID: 17177201
[TBL] [Abstract][Full Text] [Related]
3. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
[TBL] [Abstract][Full Text] [Related]
7. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
[TBL] [Abstract][Full Text] [Related]
9. Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas?
Pfister C; Ritz R; Pfrommer H; Bornemann A; Tatagiba MS; Roser F
Neurosurg Focus; 2007; 23(4):E8. PubMed ID: 17961045
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase.
Kim SH; Kim SH; Song YC; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():635-41. PubMed ID: 19723114
[TBL] [Abstract][Full Text] [Related]
11. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
Joki T; Heese O; Nikas DC; Bello L; Zhang J; Kraeft SK; Seyfried NT; Abe T; Chen LB; Carroll RS; Black PM
Cancer Res; 2000 Sep; 60(17):4926-31. PubMed ID: 10987308
[TBL] [Abstract][Full Text] [Related]
12. Effect of systemic celecoxib on human meningioma after intracranial transplantation into nude mice.
Friedrich S; Schwabe K; Grote M; Krauss JK; Nakamura M
Acta Neurochir (Wien); 2013 Jan; 155(1):173-82. PubMed ID: 23143216
[TBL] [Abstract][Full Text] [Related]
13. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
Liu W; Chen Y; Wang W; Keng P; Finkelstein J; Hu D; Liang L; Guo M; Fenton B; Okunieff P; Ding I
Am J Clin Oncol; 2003 Aug; 26(4):S103-9. PubMed ID: 12902866
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.
Song X; Lin HP; Johnson AJ; Tseng PH; Yang YT; Kulp SK; Chen CS
J Natl Cancer Inst; 2002 Apr; 94(8):585-91. PubMed ID: 11959891
[TBL] [Abstract][Full Text] [Related]
15. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
Wu R; Abramson AL; Shikowitz MJ; Dannenberg AJ; Steinberg BM
Clin Cancer Res; 2005 Sep; 11(17):6155-61. PubMed ID: 16144915
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.
Waskewich C; Blumenthal RD; Li H; Stein R; Goldenberg DM; Burton J
Cancer Res; 2002 Apr; 62(7):2029-33. PubMed ID: 11929821
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Ferrandina G; Ranelletti FO; Legge F; Lauriola L; Salutari V; Gessi M; Testa AC; Werner U; Navarra P; Tringali G; Battaglia A; Scambia G
Clin Cancer Res; 2003 Oct; 9(12):4324-31. PubMed ID: 14555502
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
20. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells.
Kern MA; Schubert D; Sahi D; Schöneweiss MM; Moll I; Haugg AM; Dienes HP; Breuhahn K; Schirmacher P
Hepatology; 2002 Oct; 36(4 Pt 1):885-94. PubMed ID: 12297835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]